« Back
Home /
Deschloroclozapine

Deschloroclozapine

Item no.	HY-42110-10mg
Manufacturer	MedChem Express
CASRN	07.07.1977
Amount	10 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 g 50 mg 5 g 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.83
Formula	C18H20N4
Citations	Acta Neuropathol Commun. 2024 Nov 22;12(1):179. Behav Brain Res. 2023 Sep 16;114674. bioRxiv. 2020 May 18. bioRxiv. 2023 Apr 24. bioRxiv. 2023 Dec 22. bioRxiv. 2023 Jun 24. bioRxiv. 2023 Jun 7. bioRxiv. 2023 Mar 6. bioRxiv. 2023 May 23. bioRxiv. 2023 Nov 17. bioRxiv. 2024 Feb 12. bioRxiv. 2024 July 02. bioRxiv. 2024 Jun 27:2024.06.22.600167. bioRxiv. 2024 Jun 28:2024.06.28.601172. bioRxiv. 2024 Mar 12. bioRxiv. 2024 November 03. bioRxiv. July 19, 2021. bioRxiv. November 25, 2021. Cell Rep Methods. 2024 Oct 21;4(10):100881. Cell. 2023 Nov 22;186(24):5394-5410.e18. eNeuro. 2023 Oct 9:ENEURO.0162-23.2023. eNeuro. 2025 Feb 7:ENEURO.0359-24.2025. Eur J Neurosci. 2023 Sep 12. Front Aging Neurosci. 2023 Mar 23;15:1142055. iScience. 2021 Aug 30;24(9):103066. IUBMB Life. 2024 Sep 2. J Cereb Blood Flow Metab. 2021 Apr 14;271678X211007949. Nat Commun. 2022 Apr 25;13(1):2233. Nat Commun. 2022 Nov 4;13(1):6662. Nat Commun. 2023 Feb 24;14(1):1066. Nat Commun. 2023 Feb 28;14(1):971. Nat Commun. 2023 Jul 24;14(1):4456. Nat Commun. 2023 Oct 24;14(1):6758. Nat Neurosci. 2020 Sep;23(9):1157-1167. Nat Neurosci. 2024 Dec 3. Neuromethods. 2023 Feb 7. Neuron. 2021 Oct 20;109(20):3312-3322.e5. Neuron. 2022 Jan 28;S0896-6273(22)00047-2. Neuron. 2024 Oct 3:S0896-6273(24)00660-3. Neuropharmacology. 2023 May 8;109576. Neuropsychopharmacology. 2020 Oct;45(11):1793-1798. Neuropsychopharmacology. 2024 Jul 29. Patent. US20210275696A1. Research Square Preprint. 2023 Jul 24. Research Square Print. 2023 Mar 27. Sci Adv. 2024 Jul 19;10(29):eadp5239. Adv Sci (Weinh). 2025 Feb 14:e2406192. The University of Chicago. 2023 Dec. [1]Maggs JL, et al. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther. 1995;275(3):1463-1475. [2]Hu F, et al. <sup>18</sup>F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. Eur J Med Chem. 2021;213:113047. [3]Upright NA, et al. Effect of chemogenetic actuator drugs on prefrontal cortex-dependent working memory in nonhuman primates. Neuropsychopharmacology. 2020;45(11):1793-1798.
Smiles	CN1CCN(C2=NC3=CC=CC=C3NC4=CC=CC=C42)CC1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	07.07.1977
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	mAChR
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	292.386
Product Description	Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with Ki of 6.3 and 4.2 nM, respectively. [11C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging[1][2][3].
Manufacturer - Research Area	Neurological Disease
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Isoform	mAChR3; mAChR4
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-42110-10mg-safety-datasheet.pdf